<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01891318</url>
  </required_header>
  <id_info>
    <org_study_id>CASE7312</org_study_id>
    <nct_id>NCT01891318</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study</brief_title>
  <official_title>Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Case Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Case Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase I/II trial studies the ability to stop brain metastases from coming back after&#xD;
      treatment with radiosurgery followed by surgical resection. It will also evaluate the side&#xD;
      effects of these combined treatments and help determine the best radiosurgery dose.&#xD;
      Radiosurgery focuses the x-rays directly to the tumor and cause less damage to the normal&#xD;
      tissue in the brain.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the safety (risk of acute and long-term toxicities) of neoadjuvant&#xD;
      radiosurgery at escalating doses followed by surgical resection of brain metastases. (Phase&#xD;
      I)&#xD;
&#xD;
      II. To determine the local control of brain metastases treated with neoadjuvant radiosurgery&#xD;
      followed by surgical resection. (Phase II)&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the rate of distant brain failure when brain metastases are managed with&#xD;
      neoadjuvant radiosurgery followed by surgical resection.&#xD;
&#xD;
      II. To estimate the rate of salvage surgery, whole brain radiation therapy (WBRT), or&#xD;
      stereotactic radiosurgery (SRS) for participants treated with neoadjuvant radiosurgery&#xD;
      followed by surgical resection.&#xD;
&#xD;
      III. To determine the rate of radiation necrosis/steroid dependency. IV. To determine the&#xD;
      radiobiologic impact of neoadjuvant radiosurgery for resected brain metastases.&#xD;
&#xD;
      OUTLINE: This is a phase I, dose-escalation study of radiosurgery followed by a phase II&#xD;
      study.&#xD;
&#xD;
      The following outcomes were removed from the protocol in an amendment:&#xD;
&#xD;
        -  Changes in neurocognitive function as measured by the Hopkins Verbal Learning Test&#xD;
           (HVLT), Controlled Oral Word Association (COWA) &amp; Trailmaking Test B, and Trailmaking&#xD;
           Test A&#xD;
&#xD;
        -  QOL measured by FACT-BR and EORTC-QLQ30&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 3, 2013</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD)</measure>
    <time_frame>Day 0</time_frame>
    <description>MTD of radiosurgery determined by dose-limiting toxicities graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.0 (Phase I)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of participants without local failure (Phase II)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Local control of brain metastases, as measured by proportion of participants without local failure (Local failure is tumor progression of the metastasis treated on the study)&#xD;
(Phase II)&#xD;
The Kaplan-Meier method will be used.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with distant brain failure</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Rate of distant brain failure, defined as progression of brain metastases outside of the brain metastasis treated on study. The Kaplan-Meier method will be used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of radiation necrosis/steroid dependency</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Rate of radiation necrosis/steroid dependency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of salvage treatment</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Number of patients that have any salvage treatment, including surgery, stereotactic radiosurgery (SRS), or whole brain radiation therapy (WBRT)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Tumors Metastatic to Brain</condition>
  <arm_group>
    <arm_group_label>Treatment (radiosurgery, surgery)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo radiosurgery on day 0. Within 2 weeks, patients undergo surgical resection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiosurgery</intervention_name>
    <description>Undergo radiosurgery</description>
    <arm_group_label>Treatment (radiosurgery, surgery)</arm_group_label>
    <other_name>radiation surgery</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>therapeutic conventional surgery</intervention_name>
    <description>Undergo surgical resection</description>
    <arm_group_label>Treatment (radiosurgery, surgery)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>quality-of-life assessment</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Treatment (radiosurgery, surgery)</arm_group_label>
    <other_name>quality of life assessment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have a prior histologic diagnosis of cancer other than small cell lung cancer,&#xD;
             lymphoma, and germ cell histologies&#xD;
&#xD;
          -  Magnetic resonance imaging (MRI) evidence of 1-4 brain metastases, with at least one&#xD;
             lesion &gt; 20 mm and ≤ 50 mm in maximal diameter and determined to be appropriate for&#xD;
             SRS and gross total resection; all other brain metastases are appropriate for SRS&#xD;
&#xD;
          -  Patient can have prior SRS to lesions other than the one planned for neoadjuvant SRS&#xD;
             and resection&#xD;
&#xD;
          -  Patient must have a Karnofsky performance score of ≥ 70&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient deemed medically unfit to undergo surgical resection of brain metastasis&#xD;
&#xD;
          -  Prior whole brain radiotherapy&#xD;
&#xD;
          -  Patient with contraindication for imaging with MRI&#xD;
&#xD;
          -  Inability to participate in study activities due to physical or mental limitations&#xD;
&#xD;
          -  Inability or unwillingness to return for all the required follow-up visits&#xD;
&#xD;
          -  At the time of planning, unable to deliver 10 Gray (Gy) or less to optic nerve/chiasm&#xD;
&#xD;
          -  Tumor located in the brainstem&#xD;
&#xD;
          -  Imaging or cytologic evidence of leptomeningeal disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Erin Murphy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Case Comprehensive Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Erin Murphy, MD</last_name>
    <phone>1-866-223-8100</phone>
    <email>TaussigResearch@ccf.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic, Case Comprehensive Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin Murphy, MD</last_name>
      <phone>866-223-8100</phone>
      <email>TaussigResearch@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Erin Murphy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>June 26, 2013</study_first_submitted>
  <study_first_submitted_qc>June 28, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 3, 2013</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

